Madrigal Pharmaceuticals (MDGL) closed at $427.39 on November 13, 2026, up 0.5% from the previous close, on volume of 424,915 shares (30-day average 470,366).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 22, 2026 | 12 Leg Put Combo with Ratio | 18-Dec-26240 : 250[2x] : 260 : 290 : 300[2x] : 310 : 340 : 350[2x] : 360 : 390 : 400[2x] : 410 P | 1,200 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Madrigal Earnings Call Highlights Rezdiffra Growth
TipRanks (Sat, 14-Nov 8:09 PM ET)
Globe Newswire (Sat, 14-Nov 12:05 PM ET)
Globe Newswire (Fri, 13-Nov 6:00 PM ET)
Newsfile (Fri, 13-Nov 1:01 PM ET)
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
Globe Newswire (Fri, 13-Nov 8:00 AM ET)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Thu, 12-Nov 7:10 AM ET)
MSCI announces November index changes, adds Moderna to World Index
Seeking Alpha News (Thu, 12-Nov 5:12 AM ET)
Newsfile (Thu, 12-Nov 5:05 AM ET)
PRNewswire (Wed, 11-Nov 8:38 PM ET)
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Madrigal Pharmaceuticals trades on the NASDAQ stock market under the symbol MDGL.
As of November 13, 2026, MDGL stock price climbed to $427.39 with 424,915 million shares trading.
MDGL has a beta of 0.02, meaning it tends to be less sensitive to market movements. MDGL has a correlation of 0.00 to the broad based SPY ETF.
MDGL has a market cap of $9.87 billion. This is considered a Mid Cap stock.
Last quarter Madrigal Pharmaceuticals reported $431 million in Revenue and $1.83 earnings per share. This beat revenue expectation by $27 million and exceeded earnings estimates by $2.92.
In the last 3 years, MDGL traded as high as $615.00 and as low as $151.01.
The top ETF exchange traded funds that MDGL belongs to (by Net Assets): VTI, VB, XBI, VBK, VXF.
MDGL has underperformed the market in the last year with a price return of -17.0% while the SPY ETF gained +13.4%. MDGL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -15.8% and -0.7%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
MDGL support price is $410.55 and resistance is $439.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MDGL shares will trade within this expected range on the day.
